NOURESS Drug Patent Profile

Which patents cover Nouress, and when can generic versions of Nouress launch?

Nouress is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. There are nineteen patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in NOURESS is cysteine hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cysteine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Nouress

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (cysteine hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NOURESS

International Patents:	1
US Patents:	19
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOURESS

US Patents and Regulatory Information for NOURESS

NOURESS is protected by nineteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y

International Patents for NOURESS

See the table below for patents covering NOURESS around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3070798	COMPOSITION DE CYSTEINE ET INJECTION (CYSTEINE COMPOSITION AND INJECTION)
Canada	3070798

Supplementary Protection Certificates for NOURESS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0107734	93C0042	Belgium		PROD. NAME TETRAKIS (2-METHOXY-ISOBUTYL-ISONITRILE). CUIVRE (I) TETRAFLUOROBORATE, DIHYDRATE DE CHLORURE STANNEUX, CHLORHYDRATE DE L-CYSTEINE (MONOHYDRATE); REG NO/DATE 923 IS 3 F 12/ 19900924 ; FIRST REG CC NO DATE IE PA 200/9/1 19900817

NOURESS Market Analysis and Financial Projection

Last updated: February 9, 2026

What Is the Market and Investment Outlook for NOURESS?

NOURESS is a hypothetical pharmaceutical drug, and as of now, there is no publicly available data indicating its approval status or development stage. The assessment below extrapolates typical investment considerations based on drug development, regulatory pathways, and market dynamics.

What Is the Development and Approval Status of NOURESS?

• No official FDA or EMA approval records for NOURESS exist.
• Presumed to be in preclinical, Phase I, or Phase II trials based on available industry data.
• Typical clinical phases last 1-2 years, with approval potentially 3-5 years away post-Phase III.
• Patent protection assumed; patent life and expiration scheduled accordingly.

What Is the Therapeutic Area and Market Potential?

• Without detailed indication data, assessing market size is speculative.
• For a skeleton analysis, consider common segments: oncology, neurology, infectious diseases, rare diseases.
• Large markets: Oncology (~$200 billion in 2022 globally), neurology (~$33 billion).
• Niche markets: Orphan and rare diseases present less competition with higher pricing.

What Are the Financial and Strategic Fundamentals?

• R&D Investment: Estimated at $1-2 billion from preclinical to approval, depending on the indication and trial complexity.
• Manufacturing Costs: Typically 20-30% of sales; economies of scale can influence margins.
• Pricing Strategy: Innovative drugs often price between $30,000 to over $100,000 annually per patient.
• Reimbursement landscape: Payer uptake depends on demonstrated value, unmet need, and pricing.

What Are the Risks and Rewards?

Risk Factors	Impact
Regulatory delays or denials	Significant delay or loss of market access
Clinical trial failures	Abortive development, sunk costs
Market competition	Entry of similar or superior therapies can diminish market share
Patent litigation	Can extend exclusivity or lead to generic competition delays

Reward Factors	Potential Benefits
Market exclusivity	20-year patent protection, with data exclusivity periods
High unmet medical need	Pricing power and expedited regulatory pathways in some cases
Fast-track designation	Potential for accelerated approval if qualifying criteria are met

Which Regulatory Pathways Are Likely?

• Breakthrough Therapy or Priority Review status may be available if NOURESS demonstrates substantial improvement over existing therapies.
• Orphan Drug designation could provide seven-year market exclusivity and fee waivers if indicated for rare diseases.
• Fast-track pathways can shorten development timelines by providing enhanced interactions with regulators.

How Does Competitive Landscape Shape Investment?

• Establish the number of competitors targeting the same indication.
• Consider existing standard-of-care treatments, their efficacy, safety profile, and market share.
• Evaluate pipeline drugs from major pharmaceutical firms through ClinicalTrials.gov and industry reports for near-term competitors.

What Are the Key Financial and Business Metrics?

• Break-even point: Sales volume times price minus costs aligning with projected R&D and commercial investment.
• Return on investment (ROI): Depends on pipeline success, pricing power, and market penetration.
• Risk-adjusted net present value (NPV): Typically used to value early-stage assets, factoring in probability of success (PoS).

What Is the Investment Thesis for NOURESS?

• High risk: Clinical failure rates in pharma range from 60-70%, especially in early phases.
• High reward potential: If indications are unmet needs with high pricing and regulatory incentives.
• Strategic value: Licensing deals, partnerships, or acquisition targets.

Key Takeaways

• Investment in NOURESS hinges on clinical progress, regulatory support, and market dynamics.
• No current phase or approval data; speculative with inherent high risk.
• Market size, patent protection, and unmet need are primary influencers of value.
• Competitive landscape and regulatory incentives shape potential profit margins.
• Industry-standard development timelines suggest multiple years before commercialization, with corresponding capital requirements.

FAQs

1. What is an acceptable probability of success for a drug at early stages?
   Typically, 10-15% for Phase I to Phase III transitions; increases with phase progression.

2. How do orphan drug designations affect market potential?
   They grant market exclusivity, fee waivers, and tax incentives, which can significantly enhance profitability for rare disease therapies.

3. What are typical costs for bringing a drug like NOURESS to market?
   Between $1-2 billion, including clinical trials, regulatory fees, manufacturing setup, and commercialization.

4. What is the significance of patent protection for a new drug?
   It provides a 20-year exclusivity window, during which competitors cannot produce generic equivalents.

5. How do regulator-designated expedited programs impact development?
   They can reduce approval timelines by months or years, accelerating revenue generation.

---

Sources

[1] IQVIA Institute for Human Data Science, "The Global Use of Medicine in 2022," 2022.
[2] FDA Guidance Documents, "Regulatory Pathways for Drugs," 2022.
[3] Pharmaprojects Database, 2023.